Form 4: Skye Bioscience Sees Major Share Acquisition by 5AM Partners

5AM Partners and related entities significantly increased their stake in Skye Bioscience through a recent transaction.

Summary

• On March 13, 2024, 5AM Partners VII, LLC, along with affiliated entities, acquired 450,000 shares of Skye Bioscience, Inc. common stock at a price of $10 per share.
• Following this transaction, 5AM Ventures VII, L.P. beneficially owns 8,393,520 shares, 5AM Ventures II, L.P. owns 1,718,189 shares, and 5AM Co-Investors II, L.P. owns 67,796 shares.
• The reporting persons include several entities and individuals associated with 5AM Partners, including Andrew J. Schwab, John Diekman, Kush Parmar, and Scott M. Rocklage, all of whom may have shared voting and investment power over the securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard filing indicating a significant share purchase, which could be seen as a positive signal, but without further context, it's difficult to gauge the overall impact.

Positives

• The acquisition of a significant number of shares by 5AM Partners could be interpreted as a sign of confidence in Skye Bioscience's future prospects.

Risks

• The filing itself doesn't present any immediate risks, but it's important to monitor future filings and company announcements to understand the long-term implications of this increased ownership.

Industry Context

Form 4 filings are standard practice when significant changes in ownership occur, providing transparency to the market.

Stakeholder Impact

• Shareholders may react to the news of increased ownership by 5AM Partners.
• The increased stake could influence the company's strategic direction.

Key Dates